Raymond James Financial Inc. Has $8.93 Million Position in Qiagen N.V. $QGEN

Raymond James Financial Inc. reduced its holdings in Qiagen N.V. (NYSE:QGEN) by 10.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 222,314 shares of the company’s stock after selling 26,000 shares during the period. Raymond James Financial Inc. owned 0.10% of Qiagen worth $8,926,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Qiagen in the 4th quarter valued at $202,000. GAMMA Investing LLC increased its stake in Qiagen by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock valued at $118,000 after buying an additional 1,425 shares during the last quarter. Cetera Investment Advisers grew its position in shares of Qiagen by 23.2% in the 1st quarter. Cetera Investment Advisers now owns 13,917 shares of the company’s stock valued at $551,000 after acquiring an additional 2,620 shares during the period. Avantax Advisory Services Inc. grew its position in shares of Qiagen by 30.2% in the 1st quarter. Avantax Advisory Services Inc. now owns 9,869 shares of the company’s stock valued at $396,000 after acquiring an additional 2,290 shares during the period. Finally, Federated Hermes Inc. bought a new position in shares of Qiagen in the 1st quarter valued at about $150,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on QGEN shares. Cowen reissued a “hold” rating on shares of Qiagen in a research report on Thursday, August 7th. Wall Street Zen downgraded shares of Qiagen from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 11th. UBS Group lifted their price objective on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Barclays started coverage on shares of Qiagen in a research report on Tuesday, June 24th. They issued an “overweight” rating and a $55.00 price objective for the company. Finally, Bank of America lifted their price objective on shares of Qiagen from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday, June 26th. Three research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $49.69.

Qiagen Stock Performance

NYSE QGEN opened at $46.53 on Monday. The firm has a 50-day moving average of $48.71 and a 200-day moving average of $44.16. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The stock has a market cap of $10.34 billion, a PE ratio of 27.49, a P/E/G ratio of 2.57 and a beta of 0.64. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88.

Qiagen (NYSE:QGEN) last posted its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.60. The company had revenue of $533.54 million during the quarter, compared to analysts’ expectations of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. Qiagen’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.55 EPS. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, sell-side analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.